SYROS PHARMACEUTICALS
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
SYROS PHARMACEUTICALS
Industry:
Biotechnology Genetics Life Science Pharmaceutical
Founded:
2012-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.syros.com
Total Employee:
101+
Status:
Active
Contact:
(617) 744-1340
Total Funding:
620.47 M USD
Technology used in webpage:
Domain Not Resolving HSTS Mobile Non Scaleable Content Sitelinks Search Box CrUX Top 50m DNSSEC ASP.NET Microsoft OpenResty Sectigo SSL
Similar Organizations
23andMe
23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Alvotech
Alvotech is a biotechnology company that specializes in making biosimilars to create biologic medicines.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Avidity Biosciences
Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.
Element Biosciences
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets.
Eyenovia
Eyenovia is a biopharmaceutical company that provides a portfolio of next generation topical eye treatments.
Standard BioTools
Standard BioTools is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.
Lifebit
Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Synthego
Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Verve Therapeutics
Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.
Current Advisors List
Board_member
2014-07-01
Board_member
2017-01-01
Advisor
2013-01-01
Board_member
Board_member
Current Employees Featured
Marsha Fanucci Director Board Of Directors and Audit Committee Chair @ Syros Pharmaceuticals
Director Board Of Directors and Audit Committee Chair
2015-01-01
Nathanael Gray Co-Founder @ Syros Pharmaceuticals
Co-Founder
Conley Chee Chief Commercial Officer @ Syros Pharmaceuticals
Chief Commercial Officer
Nancy Simonian CEO @ Syros Pharmaceuticals
CEO
2012-06-01
Richard Young Founder and Director @ Syros Pharmaceuticals
Founder and Director
2013-01-01
Jay Bradner Co-Founder @ Syros Pharmaceuticals
Co-Founder
Gregg Beloff CFO @ Syros Pharmaceuticals
CFO
Jeremy Springhorn Chief Business Officer @ Syros Pharmaceuticals
Chief Business Officer
2017-11-01
Jason Haas Chief Financial Officer @ Syros Pharmaceuticals
Chief Financial Officer
2021-10-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-07-07 | TYME | TYME acquired by Syros Pharmaceuticals | 60 M USD |
| 2020-12-07 | Orsenix | Orsenix acquired by Syros Pharmaceuticals | 12 M USD |
Investors List
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Syros Pharmaceuticals
Flagship Pioneering
Flagship Pioneering investment in Post-IPO Equity - Syros Pharmaceuticals
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Syros Pharmaceuticals
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Syros Pharmaceuticals
Blue Owl
Blue Owl investment in Post-IPO Equity - Syros Pharmaceuticals
Invus
Invus investment in Post-IPO Equity - Syros Pharmaceuticals
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Syros Pharmaceuticals
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Syros Pharmaceuticals
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Syros Pharmaceuticals
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Syros Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-02 | After 2 partners walk away, Syros cuts 35% of workforce and lines up new CEO |
Official Site Inspections
http://www.syros.com Semrush global rank: 9.45 M Semrush visits lastest month: 379
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Syros Pharmaceuticals"
Company Information :: Syros Pharmaceuticals, Inc. (SYRS)
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. View Profile View Management Team. Contact Information. …See details»
Syros Imaging
Manage cases within your organization, and create user groups and user roles to collaborate internally and externally. Learn More. Research & Education. Reports, Research collaboration, …See details»
About Us :: Syros Pharmaceuticals, Inc. (SYRS)
The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it can lead to …See details»
Syros Pharmaceuticals - Crunchbase Company Profile & Funding
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has …See details»
Syros Announces Planned CEO Leadership Transition and Strategic ...
Oct 2, 2023 Syros is streamlining its organization and implementing an approximately 35% workforce reduction to reflect its focus on the clinical development of tamibarotene and …See details»
Board of Directors :: Syros Pharmaceuticals, Inc. (SYRS)
Fanucci serves on the boards of directors of several biotech companies, including Alnylam Pharmaceuticals, FORMA Therapeutics, Ironwood Pharmaceuticals and Momenta …See details»
Leadership :: Syros Pharmaceuticals, Inc. (SYRS)
Gerald brings more than 20 years of senior leadership and legal experience in the biotechnology industry. Before joining Syros, he was Executive Vice President of Business Operations and General Counsel at Tokai Pharmaceuticals, where …See details»
Syros - The Org
Syros Pharmaceuticals is a life sciences company that is focused on treating diseases by mapping gene regulatory circuits. Industries. Biotechnology, Manufacturing + 1. Headquarters. …See details»
Syros Pharmaceuticals (SYRS) Company Profile & Description
5 days ago Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product …See details»
Syros Pharmaceuticals, Inc. (SYRS) - Yahoo Finance Canada
Description . Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product …See details»
Syros Pharmaceuticals - Funding, Financials, Valuation & Investors
Syros Pharmaceuticals is registered under the ticker NASDAQ:SYRS . Their stock opened with $12.50 in its Jun 30, 2016 IPO. Syros Pharmaceuticals is funded by 23 investors. Deep Track …See details»
Investor Relations :: Syros Pharmaceuticals, Inc. (SYRS)
Feb 28, 2025 Syros Pharmaceuticals, Inc. Symbol Nasdaq: SYRS. Price. Change. Volume. 52 week Low/High. Day Low/High. Company Overview. Syros is committed to developing new …See details»
Platform :: Syros Pharmaceuticals, Inc. (SYRS)
Our gene control platform has served as the foundation for our clinical stage pipeline and has been used to identify targets and biomarkers for drug development with the aim of providing a …See details»
Syros Pharmaceuticals - VentureRadar
" Syros Pharmaceuticals is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating …See details»
Syros Pharmaceuticals Inc Company Profile - Overview
Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers …See details»
Syros Tourist Lodgements Association - Visit Syros
The Syros Tourist Lodgements Association would like to welcome you to its official website and invite you, through this first-time visit, to explore the majestic and fabulous island of Syros. Get …See details»
Syros 2025 Company Profile: Valuation, Investors, Acquisition
Syros General Information Description. Distributor of packaged avocado and guacamole food products intended to serve supermarkets, restaurant chains and the meal box industry. The …See details»
Our People :: Syros Pharmaceuticals, Inc. (SYRS)
Working at Syros is an incredibly rewarding experience. I work on challenging and stimulating projects while receiving guidance and support from colleagues who are always willing to share …See details»
Syros Pharmaceuticals Announces Appointment of CEO Nancy …
WATERTOWN, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals, the leader in the discovery and development of novel gene control therapies, announced today that Chief Executive …See details»
saint of athens revives century-old cycladic building as sunlit bar ...
3 days ago Saint of Athens breathes new life into a 1900s Cycladic building with LIAKO, a bar–restaurant in the heart of Syros that celebrates light and history. Set next to the Town Hall …See details»